Comprehensive molecular biomarker identification in breast cancer brain metastases

  title={Comprehensive molecular biomarker identification in breast cancer brain metastases},
  author={Hans-Juergen Schulten and Mohammed Hasan Bangash and Sajjad Karim and Ashraf Dallol and Deema Hussein and Adnan A. Merdad and Fatma Khinaifis Al-thoubaity and Jaudah Al-Maghrabi and Awatif Jamal and Fahad Al-Ghamdi and Hani Choudhry and Saleh Baeesa and Adeel Ga Chaudhary and Mohammed Hussein Al-Qahtani},
  journal={Journal of Translational Medicine},
Breast cancer brain metastases (BCBM) develop in about 20–30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p < 0… 

Identification of potential genes related to breast cancer brain metastasis in breast cancer patients

The present study attempted to identify novel diagnostic and prognostic biomarkers of BCBM by identifying ten key genes, including LAMA4, COL1A1, COL5A2, COL3A1), which were potentially correlated with BCBM in human epidermal growth factor 2 (HER2) expression.

Clinical significance and prognostic value of small nucleolar RNA SNORA38 in breast cancer

SNORA38 is an important carcinogenic snoRNA in breast cancer and might be a prognostic biomarker for breast cancer, which is suggested to be related to breast cancer stemness.

Recognition of the organ-specific mutations in metastatic breast cancer by circulating tumor cells isolated in vivo.

Evidence is provided that the authors can detect gene mutation information for obtaining the biological characteristics by CTCs using CellCollector, and different metastasis sites contain specific high-frequency mutation genes, which provide guidance to the accurate gene therapy.

CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases

CILP offers new insights into the pathogenesis of BCBM, which will facilitate the development of novel targets for BCBM patients and may be a putative gene involved in BCBM.

CILP Inhibits Brain Metastasis by Meditating Mast Cells via the MAPK Signaling Pathway in Breast Cancer

CILP can influence the progression of BRCA favored for BMs through meditating mast cells via the MAPK signaling pathway through the GO and KEGG pathway analysis.

Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling

expression level of a small set of genes from primary tumors was found to predict BM development, distinctly from metastasis to other organs, and the correlated oxidative phosphorylation pathway was strongly correlated with BM risk.

A Need for More Molecular Profiling in Brain Metastases

Appreciating the importance of biomarker analyses in BrM tissue, including how it may identify specific drivers of BrM, is critical for the development of more effective treatment strategies to improve outcomes for this growing patient population.

SNORA71B promotes breast cancer cells across blood–brain barrier by inducing epithelial-mesenchymal transition

SNORA71B promotes BC cells across the BBB partly via inducing EMT, and significantly promoted proliferation, migration, and invasion of BC cells with different BM abilities.

Seeking for Correlative Genes and Signaling Pathways With Bone Metastasis From Breast Cancer by Integrated Analysis

Osteoclast differentiation and rheumatoid arthritis were two significantly enriched signaling pathways for DEGs in the bone metastasis of breast cancer.



Gene Expression Profiling of Breast Cancer Brain Metastasis

The findings, although not conclusive, reveal differentially expressed genes that might mediate the brain metastasis process in primary breast cancer patients with the distinct gene expression.

Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.

  • E. BrogiC. Murphy A. Seidman
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
Expression of antigens commonly associated with breast carcinoma does not differ significantly between the primary tumor and the corresponding brain metastases and a possible association between CK5/6 expression in the primary tumors and multiple versus solitary BCBM is observed.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

To determine whether there are intrinsic subtype differences between primary tumors and matched BrM and to uncover BrM-acquired alterations that are clinically actionable, and to support comprehensive profiling of metastases to inform clinical care.

Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis

Genomic and epigenomic profiling of breast brain metastasis has provided insight into the somatic events underlying this disease, which have potential in forming the basis of future therapeutic strategies.

Role of KCNMA1 gene in breast cancer invasion and metastasis to brain

Determining the relative abundance of BKCa channel expression in breast cancer metastatic to brain and the mechanism of its action in brain metastasis will provide a unique opportunity to identify and differentiate between low grade breast tumors that are at high risk for metastasis from those at low riskFor metastasis.

Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis

The first gene expression analysis of laser-captured epithelial cells from resected human brain metastases of breast cancer compared with unlinked primary breast tumors suggested that HK2 overexpression is associated with metastasis to the brain in breast cancer and it may be a therapeutic target.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity

Evaluation of pharmacological sensitivity in breast cancer cell lines representing all breast cancer subtypes suggests the BD-L signature may serve as a biomarker to identify sporadic breast cancer patients who might benefit from a therapeutic combination of PARP inhibitor and temozolomide and may be indicative of a dysfunctional BRCA1-associated pathway.

Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.

A set of candidate genes and biofunctions implicated in, so far nearly uncharacterized, molecular processes of a brain metastasis from a PTC are identified.

EGFR and HER2 signaling in breast cancer brain metastasis.

This review will first provide an overview of the HER2 and EGFR signaling pathways, then the roles that EGFR and HER2 play in breast cancer metastasis to the brain will be discussed, and the preclinical and clinical effects of EGFR- and Her2-targeted therapies on breast Cancer metastasis are summarized.